Overview

Natural Berry Extract Treatment of Hemangiomas

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled parallel group study evaluating the use of PediaBerry for the treatment of hemangiomas in infants ≤ 4 months of corrected gestation age over a 6-month treatment period. Subjects will be followed to age 18 months. A total of 44 subjects will be PediaBerry group and 22 subjects in the placebo control group.
Phase:
Early Phase 1
Details
Lead Sponsor:
Indiana University
Collaborators:
National Institute of General Medical Sciences (NIGMS)
National Institutes of Health (NIH)